Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK Phase II open-label study of ruxolitinib in myelofibrosis
2011-005066-38Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) (2 arms), sponsored by Novartis. Primary endpoint: Treatment success at 48 weeks. Started Jan 2012; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2011-005066-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005066-38.